Send me real-time posts from this site at my email

Watchlist Update: 1-14-2020 - HZNP - Horizon Therapeutics - Analyst Comments

$HZNP - On our trading list. A good longer-term biotech/drug stock.


JMP Securities analyst Donald Ellis raised his price target on Horizon Therapeutics to $47 and kept his Outperform rating after the company increased its peak sales estimates for KRYSTEXXA and Teprotumumab from over $750M to over $1B

The analyst cites the company's multiple immunomodulation studies for KRYSTEXXA showing improved responder rates and also points to the March 8th PDUFA date for Tepro where he "fully" expects approval, with additional plans for assessing further indications post-approval.


$HZNP, Horizon Therapeutics Public Limited Company / H1


Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue